Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2018Cancer MedicineOpen Access

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMasahiro MatsukiTHTaisuke HoshiYYYuji Yamamoto

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Matsuki et al. (2018) studied this question.

synapsesocial.com/papers/69df2b39d85e58e37b7a1905https://doi.org/10.1002/cam4.1517
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization2014 · 283 citations
  2. 2Sorafenib in Advanced Hepatocellular Carcinoma2008 · 13,126 citations
  3. 3Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/52006 · 1,550 citations
  4. 4BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis2004 · 4,060 citations
  5. 5Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development2015 · 79 citations